• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
YAO Aihong, CHANG Yujie, JIANG Cheng, SUN Haiying. Research progress of Polo-like kinase 1 inhibitors targeting Polo-box domain[J]. Journal of China Pharmaceutical University, 2016, 47(1): 1-8. DOI: 10.11665/j.issn.1000-5048.20160101
Citation: YAO Aihong, CHANG Yujie, JIANG Cheng, SUN Haiying. Research progress of Polo-like kinase 1 inhibitors targeting Polo-box domain[J]. Journal of China Pharmaceutical University, 2016, 47(1): 1-8. DOI: 10.11665/j.issn.1000-5048.20160101
shu

Research progress of Polo-like kinase 1 inhibitors targeting Polo-box domain

More Information
    Graphical Abstract
    • Abstract
  • The over-expression of Polo-like kinase 1(Plk1)is critical in the production and progression of multiple human tumors and is recognized as an effective target for the development of novel anti-cancer drugs. Currently a variety of small molecules targeting ATP or substrate binding sites have entered different stages of clinical trials. Polo-box domain(PBD)is a unique domain of Plks which plays an important role in the sub-cellular location of Plks and in the recognition of their substrates, therefore it has become an attractive target for the development of novel target-directed Plk1 inhibitors. In this paper, PBD function of Plk1 was introduced, the progress of small molecule and phosphoserine/phosphothreonine contained short peptide Plk1 inhibitors targeting PBD is summarized. Further development of this kind of inhibitors is also proposed.
    • FullText(HTML)
    • References (39)
  • [1]
    Lobjois V,Jullien D,Bouché JP,et al.The polo-like kinase 1 regulates CDC25B-dependent mitosis entry[J].Biochim Biophys Acta,2009,1793(3):462-468.
    [2]
    Hansen DV,Loktev AV,Ban KH,et al.Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFbetaTrCP-dependent destruction of the APC inhibitor Emi1[J].Mol Cell Biol,2004,15(12):5623-5634.
    [3]
    Barr FA, Silljé HH, Nigg EA, et al. Polo-like kinase and the orchestration of cell division[J].Nat Rev Mol Cell Biol,2004,5(6):429-440.
    [4]
    Lowery DM,Lim D,Yaffe MB.Structure and function of polo-like kinases[J].Oncogene,2005,24(2):248-259.
    [5]
    Xu J,Shen C,Wang T,et al.Structural basis for the inhibition of polo-like kinase 1[J].Nat Struct Mol Biol,2013,20(9):1047-1053.
    [6]
    Jang Y,Lin CY,Ma S,et al.Functional studies on the role of the C-terminal domain of mammalian polo-like kinase[J].Proc Natl Acad Sci U S A,2002,99(4):1984-1989.
    [7]
    Fisher RAH,Ferris DK.The functions of polo-like kinases and their relevance to human disease[J].Curr Med Chem,2002,2(2):125-134.
    [8]
    Takai N,Hamanaka R,Yoshimatsu J,et al.Polo-like kinases(Plks)and cancer[J].Oncogene,2005,24(2):287-291.
    [9]
    Liu X,Erikson RL.Polo-like kinase(Plk)1 depletion induces apoptosis in cancer cells[J].Proc Natl Acad Sci U S A,2003,100(10):5789-5794.
    [10]
    Strebhardt K,Ullrich A.Targeting polo-like kinase 1 for cancer therapy[J].Nat Rev Cancer,2006,6(4):321-330.
    [11]
    Burns TF,Fei P,Scata KA,et al.Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel(taxol)-exposed cells[J].Mol Cell Biol,2003,23(16):5556-5571.
    [12]
    Xie S,Xie B,Lee MY,et al.Regulation of cell cycle checkpoints by polo-like kinases[J].Oncogene,2005,24(2):277-286.
    [13]
    Kong KL, Lu S, Gao YP, et al. Advances on the study of PLK1 inhibitors as antitumor agents[J].J China Pharm Univ(中国药科大学学报),2011,42(1):9-15.
    [14]
    Gjertsen B T,Schöffski P.Discovery and development of the polo-like kinase inhibitor volasertib in cancer therapy[J].Leukemia,2015,29(1):11-19.
    [15]
    Li S,Zhang Y,Xu W.Developments of polo-like kinase 1(Plk1)inhibitors as anti-cancer agents[J].Mini Rev Med Chem,2013,13(14):2014-2025.
    [16]
    Zhang L, Cao YH, Lu S, et al. Targeting the substrate binding domain of polo-like kinase 1:advances in the study of PBD1 inhibitors[J].Acta Pharm Sin(药学学报),2013,48(3):315-324.
    [17]
    Liu X.Targeting polo-like kinases:a promising therapeutic approach for cancer treatment[J].Transl Oncol,2015,8(3):185-195.
    [18]
    Gumireddy K,Reddy MV,Cosenza SC,et al.ON01910,a non-ATP competitive small molecule inhibitor of Plk1,is a potent anticancer agent[J].Cancer Cell,2005,7(5):275-286.
    [19]
    Chun AW,Cosenza SC,Taft DR,et al.Preclinical pharmacokinetics and in vitro activity of ON 01910,a novel anti-cancer agent[J].Cancer Chemother Pharmacol,2009,65(1):177-186.
    [20]
    Jimeno A,Li J,Messersmith WA,et al.Phase I study of ON 01910,a novel modulator of the Polo-like kinase 1 pathway,in adult patients with solid tumors[J].J Clin Oncol,2008,26(34):5504-5510.
    [21]
    Reddy MV,Venkatapuram P,Mallireddigari MR,et al.Discovery of a clinical stage multi-kinase inhibitor sodium(E)-2-{2-methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl] phenylamino}acetate(ON 01910.Na):synthesis,structure-activity relationship,and biological activity[J].J Med Chem,2011,54(18):6254-6276.
    [22]
    Elia AE,Cantley LC,Yaffe MB.Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates[J].Science,2003,299(5610):1228-1231.
    [23]
    Elia AE,Rellos P,Haire LF,et al.The molecular basis for phospho-dependent substrate targeting and regulation of Plks by the polo-box domain[J].Cell,2003,115(1):83-95.
    [24]
    Kirkland LO, McInnes C. Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics[J].Biochem Pharm,2009,77(10):1561-1571.
    [25]
    García-Alvarez B,de Cárcer G,Ibañez S,et al.Molecular and structural basis of polo-like kinase 1 substrate recognition:Implications in centrosomal localization[J].Proc Natl Acad Sci U S A,2007,104(9):3107-3112.
    [26]
    Cheng KY,Lowe ED,Sinclair J,et al.The crystal structure of the human polo-like kinase-1 Polo-box domain and its phospho-peptide complex[J].EMBO J,2003,22(21):5757-5768.
    [27]
    Yuan J,Sanhaji M,Krämer A,et al.Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo[J].Am J Pathol,2011,179(4):2091-2099.
    [28]
    Yin Z,Chen JH,Rehse PH.Thymoquinone and poloxin are slow-irreversible inhibitors to human polo-like kinase 1 polo-box domain[J].Med Col PLA,2010,24(3):136-142.
    [29]
    Lee KS,Idle JR.Pinning down the polo-box domain[J].Chem Biol,2008,15(5):415-416.
    [30]
    Reindl W,Yuan J,Krämer A,et al.Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions[J].Chem Biol,2008,15(5):459-466.
    [31]
    Oshimori N,Ohsugi M,Yamamoto T.The Plk1 target Kizuna stabilizes mitotic centrosomes to ensure spindle bipolarity[J].Nat Cell Biol,2006,8(10):1095-1101.
    [32]
    Yin Z,Song Y,Rehse PH.Thymoquinone blocks pSer/pThr recognition by Plk1 Polo-box domain as a phosphate mimic[J].ACS Chem Biol,2013,8(2):303-308.
    [33]
    Reindl W,Yuan J,Krämer A,et al.A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis[J].ChemBioChem,2009,10(7):1145-1148.
    [34]
    Watanabe N,Sekine T,Takagi M,et al.Deficiency in chromosome congression by the inhibition of plk1 Polo-box domain-dependent recognition[J].J Biol Chem,2009,284(4):2344-2353.
    [35]
    Li L,Wang X,Chen J,et al.The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation[J].Acta Pharmacol Sin,2009,30(10):1443-1453.
    [36]
    Lu J,Xin S,Meng H,et al.A novel anti-tumor inhibitor identified by virtual screen with Plk1 structure and zebrafish assay[J].PLoS One 2013,8(4):1-7.
    [37]
    Chen DX,Huang J,Liu M,et al.Design,synthesis,and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1(Plk1)inhibitors[J].Arch Pharm,2015,348(1):2-9.
    [38]
    Liu M,Huang J,Chen DX,et al.Identification of indole-3-carboxylic acids as non-ATP-competitive polo-like kinase 1(Plk1)inhibitors[J].Bioorg Med Chem.Lett,2015,25(3):431-434.
    [39]
    Yun SM,Moulaei T,Lim D,et al.Structural and
    • Related Articles

  • Related Articles

    [1]LI Xueyan, CHEN Na, JIANG Cheng. Research progress of KRAS inhibitors[J]. Journal of China Pharmaceutical University, 2024, 55(2): 257-269. DOI: 10.11665/j.issn.1000-5048.2024010801
    [2]YANG Wanwan, YE Fangyu, WU Yujia, WANG Haochen, ZHAO Li. Research progress of PARP inhibitors in cancers and their drug resistance[J]. Journal of China Pharmaceutical University, 2022, 53(5): 525-534. DOI: 10.11665/j.issn.1000-5048.20220503
    [3]YANG Qian, WANG Xiaojian. Research progress of sphingosine kinase 1 inhibitors[J]. Journal of China Pharmaceutical University, 2021, 52(6): 759-768. DOI: 10.11665/j.issn.1000-5048.20210615
    [4]ZHAN Kangning, QUAN Xu, HUANG Zhangjian, ZHAO Liwen. Research progress of protein arginine methyltransferase 5 inhibitors[J]. Journal of China Pharmaceutical University, 2021, 52(3): 371-378. DOI: 10.11665/j.issn.1000-5048.20210315
    [5]LI Zhiyan, LIU Jie, LI Bingyan, JIANG Cheng. Design, synthesis and evaluation of peptidomimetics targeting the polo-box domain of polo-like kinase 1[J]. Journal of China Pharmaceutical University, 2020, 51(3): 287-294. DOI: 10.11665/j.issn.1000-5048.20200305
    [6]LIANG Tingting, WANG Wenjie, HE Guangchao, HE Guangchao, XU Yungen. Research progress of ERK small molecule inhibitors[J]. Journal of China Pharmaceutical University, 2020, 51(3): 260-269. DOI: 10.11665/j.issn.1000-5048.20200302
    [7]SHI Jinyu, BAI Ying, PENG Kewen, ZHANG Wenhui, ZHU Qihua, XU Yungen. Research progress of PARP-1 inhibitors in combination with other drugs to overcome drug resistance[J]. Journal of China Pharmaceutical University, 2019, 50(5): 523-530. DOI: 10.11665/j.issn.1000-5048.20190503
    [8]WANG Tianshuai, YU Junjie, ZHANG Yan, ZENG Jinjin, CUI Jingxin. Advances in platinum-intercalators of DNA as antitumor agents[J]. Journal of China Pharmaceutical University, 2019, 50(5): 505-515. DOI: 10.11665/j.issn.1000-5048.20190501
    [9]GUO Yahui, LU Peng, WANG Yubin, ZHANG Huibin. Progress in the researches for antitumor NEDD8 activating enzyme inhibitors[J]. Journal of China Pharmaceutical University, 2017, 48(6): 646-653. DOI: 10.11665/j.issn.1000-5048.20170603
    [10]KONG Kai-lai, LU Shuai, GAO Yi-ping, YANG Pei, TANG Wei-fang, LU Tao. Advances on the study of PLK1 inhibitors as antitumor agents[J]. Journal of China Pharmaceutical University, 2011, 42(1): 9-15.

Catalog

    Get Citation
    PDF
    XML
    Article views (1678) PDF downloads (2324) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：302646

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return